Samsung Biologics informs you about FSS's audit review
On April 4th, the Financial Supervisory Service (FSS) officially announced that it will conduct an audit review of 172 companies, including Samsung Biologics.
On the same day, Samsung Biologics received official notification from the FSS regarding the audit review.
This audit review is an extension of the audit supervision conducted by the Korean Institute of Certified Public Accountants (KICPA) last year, and is not a “special audit” as reported in the press. Last year’s KICPA audit supervision already confirmed that Samsung Biologics bookkeeping standards were in compliance with the legal and ethical standards.
Such an FSS audit review is usually concluded without a separate notification, unless any specific issues are discovered.
Samsung Biologics will endeavor to clearly prove the legality of our bookkeeping standards and facilitate a quick resolution to the audit review.
Samsung Biologics will continue to provide the best quality services to our customers and continuously enhance our shareholder value, based on transparent and ethical management practices.
Thank you.
Samsung Biologics informs you about FSS's audit review
On April 4th, the Financial Supervisory Service (FSS) officially announced that it will conduct an audit review of 172 companies, including Samsung Biologics.
On the same day, Samsung Biologics received official notification from the FSS regarding the audit review.
This audit review is an extension of the audit supervision conducted by the Korean Institute of Certified Public Accountants (KICPA) last year, and is not a “special audit” as reported in the press. Last year’s KICPA audit supervision already confirmed that Samsung Biologics bookkeeping standards were in compliance with the legal and ethical standards.
Such an FSS audit review is usually concluded without a separate notification, unless any specific issues are discovered.
Samsung Biologics will endeavor to clearly prove the legality of our bookkeeping standards and facilitate a quick resolution to the audit review.
Samsung Biologics will continue to provide the best quality services to our customers and continuously enhance our shareholder value, based on transparent and ethical management practices.
Thank you.
Share article
Related Content